OmniAb (OABI) vs Pharming Group N.V. (PHAR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
OmniAb (OABI) has outperformed Pharming Group N.V. (PHAR) over the past year, gaining 176.4% versus a loss of 34.2%. Over five years, PHAR leads with a +2.2% price change compared with -54.3% for OABI. OmniAb is the larger company by market cap ($677.5 million vs $674.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OABI | PHAR |
|---|---|---|
| Share price | $4.66 | $9.53 |
| Market cap | $677.52M | $674.52M |
| 1-day change | +2.19% | -1.24% |
| YTD return | +146.49% | -45.39% |
| 1-year return | +176.36% | -34.22% |
| 5-year return | -54.26% | +2.22% |
| P/E ratio (TTM) | — | 73.31 |
| Forward P/E | — | 31.04 |
| EPS (TTM) | $-0.36 | $0.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.43 | $21.34 |
| 52-week low | $1.30 | $9.44 |
| Distance from 52-week high | -14.18% | -55.34% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +88.84% | +260.44% |
| Average volume | 1.45M | 22.82K |
| Shares outstanding | 145.39M | 70.78M |
| Employees | 89 | 407 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OABI has outperformed PHAR by 210.6 percentage points over the past year.
About OmniAb
OABI stock →OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 89 employees
About Pharming Group N.V.
PHAR stock →Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 407 employees
OABI vs PHAR FAQ
Which is bigger, OmniAb or Pharming Group N.V.?
OmniAb (OABI) is larger, with a market capitalization of $677.52M compared with $674.52M for Pharming Group N.V. (PHAR).
Which stock has performed better over the past year, OABI or PHAR?
OABI returned +176.36% over the past 12 months, compared with -34.22% for PHAR (price return, excluding dividends). Past performance does not predict future results.
Are OmniAb and Pharming Group N.V. in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Commercial Physical & Biological Resarch for OmniAb and Biotechnology: Pharmaceutical Preparations for Pharming Group N.V..